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Abstract
Background: Alpha-fetoprotein (AFP) is a tumor-associated glycoprotein that functions in regulation of both
ontogenic and oncogenic growth. Recent study showed that AFP can induce apoptosis or impair monocyte-
derived dendritic cell (MDDC) function. However, it is still unclear which AFP domain (D-AFP) plays major role in
this function.
Results: As expected monocytes cultured in the presence of Granulocyte Macrophage-Colony Stimulating Factor
(GM-CSF) and Interleukin-4 (IL-4) developed into MDDC. Up-regulation of HLA-DR and CD11c as well as loss of
CD14 molecules could be observed. Full length AFP (FL-AFP), domain 2 AFP (D2-AFP) and D3-AFP, but not D1-AFP,
significantly inhibited the expression of HLA-DR
high/CD11c
high and CD80
+/CD86
high molecules. In contrast, CD83
expression was substantially down-regulated in all samples. Expression of CD40 was significantly suppressed by
FL-AFP but not by any D-AFPs. Finally, both FL-AFP and D-AFP impaired the MDDC ability to secrete IL-12 (p70).
Conclusions: D2- and D3- but not D1-AFP extensively suppresses the MDDC function. All the recombinant AFP
proteins impaired the ability of MDDC to secrete IL-12.
Background
Human alpha-fetoprotein (AFP) is a tumor-associated
fetal glycoprotein that functions in regulation of both
ontogenic and oncogenic growth [1]. It consists of 15
disulfide bridges located at positions equivalent to
human albumin, leading to a three dimensional struc-
ture that is similar to human albumin [2]. One of the
biological properties of AFP is its regulatory effects on
immune responses. In hepatocellular carcinoma (HCC)
patients with high levels of AFP, antigen presenting cells
(APCs) are dysfunctional. This leads to the suppression
of T- and B-cells response [3]. Dendritic cells (DCs) are
the most potent APCs and are important for the initia-
tion of the immune response against pathogens and
tumors. In an in vitro experiment, Um et al. (2004)
reported that AFP treatment of DCs reduced the ability
of monocyte-derived DC (MDDC) to produce IL-12 and
induces apoptosis of MDDC [4]. However, it is still
unclear which domain of the AFP plays the important
role in apoptosis or impairment of the DC functions.
The aims of this study were to produce recombinant
AFP domain (D-AFP) proteins in an Escherichia coli
expression system and to investigate the immunoregula-
tory properties of each D-AFP and to compare them to
full length (FL)-AFP. Secretion of IL-12 by MDDC after
treatment with D-AFP and FL-AFP was also analyzed.
Results
Cloning, expression, and purification of alpha-fetoprotein
domains
Several E. coli expressing plasmid constructs were made to
generate the recombinant AFPs. Recombinant AFP plas-
mids containing domain 1 and domain 2 were made in
accordance with Morinaga et al (1983) [domain 1: amino
acids position 1-197, domain 2: amino acids position
198-389], and domain 3 was produced with amino acid
positions 357-590 [5]. The N-terminal of recombinant
D1-AFP and D2-AFP contain an extra 14 amino acid pep-
tide (MASMTGGQQMGRDP) while D3-AFP contains
additional 2 amino acids (MA). To aid the purification pro-
cess, all recombinant proteins also have 6xHis tag in their
C-terminal ends (LEHHHHHH). D-AFPs were successfully
expressed by Isopropyl b-D-1-thiogalactopyranoside * Correspondence: asetiyono@mrinstitute.org
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using anti-His antibody (Figures 1A &1C). They were suc-
cessfully purified by Ni-NTA column (Figure 1B).
Impact of the domains on MDDC maturation in vitro
A ss h o w ni nT a b l e1a n dF i g u r e2 ,f r e s h l yi s o l a t e d
monocytes from human PBMC (day 0) were CD14
+.
After stimulation with GM-CSF, IL-4 and LPS, a high
expression level of CD83 (day 8) (80.97 ± 2.28) was
seen, showing that MDDC was successfully derived
from blood monocytes. At the same time, up-regulation
of HLA-DR and CD11c as well as loss of CD14 mole-
cules were also observed at day 8 (Figure 2B).
Addition of AFP has previously been shown to induce
apoptosis of MMDC [4]. We added a range of AFP con-
centration between 1.56 μg/ml to 25 μg/ml and
observed that MMDC cells start to die at FL-AFP con-
centration > 12.5 μg/ml (Figure 3). We thus chose the
6.25 μg/ml (0.091 μM) as the working concentration for
most of the subsequent experiments. When AFP at con-
centration 6.25 μg/ml was added to the monocytes cul-
ture (day 0), a reduction of the mean expression level of
M D2 D1 D3
- + - + - +
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+: with IPTG
30 kDa
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Figure 1 Purification of the AFP domains. (A) SDS-PAGE of total lysates without or with beta-gal induction (control and induction were
denoted as - or + respectively). Gels were stained with Coomassie blue. M denotes protein marker. (B) Coomassie stained gels of purified
proteins from each domain with molecular weight of 24.8 kDa (D1) and 24.4 kDa for D2 and D3. (C) Gel from B) was transferred to the
nitrocellulose membrane and blotted with an anti-His antibody.
Table 1 Comparison of the phenotypic characteristic of MDDC at three stages dependent on treatments
Surface Marker Expression (%)
CD14
+ HLA-DR
high CD80
+ CD40
+ CD83
+
/CD11c
high /CD86
high
Monocytes* 91.03 ± 0.75 42.70 ± 2.04 0.03 ± 0.03 22.83 ± 9.92 2.20 ± 0.70
Non Treated imMDDC 5.80 ± 2.91 67.47 ± 3.94 1.33 ± 0.10 52.47 ± 14.98 15.83 ± 6.70
mMDDC 5.17 ± 0.82 91.4 ± 3.12 92.57 ± 1.52 96.30 ± 0.75 80.97 ± 2.28
FL-AFP imMDDC 1.30 ± 0.60 47.73 ± 4.45 2.47 ± 0.43 38.50 ± 7.30 10.33 ± 2.68
mMDDC 1.47 ± 0.57 53.70 ± 3.94** 17.67 ± 2.35** 65.57 ± 0.30** 27.17 ± 3.94**
D1-AFP imMDDC 2.40 ± 1.47 56.27 ± 2.50 3.50 ± 0.79 54.80 ± 11.47 12.30 ± 2.10
mMDDC 1.87 ± 0.38 73.63 ± 4.76 65.47 ± 7.03 90.07 ± 3.66 59.27 ± 8.90
D2-AFP imMDDC 1.07 ± 0.17 44.30 ± 2.04 6.37 ± 1.09 63.53 ± 10.02 17.10 ± 3.65
mMDDC 2.40 ± 0.40 41.57 ± 6.20** 28.20 ± 4.59** 87.63 ± 5.51 34.70 ± 3.43**
D3-AFP imMDDC 1.90 ± 0.53 48.27 ± 2.28 6.90 ± 1.65 66.30 ± 9.89 21.97 ± 5.88
mMDDC 2.07 ± 0.09 43.80 ± 6.91** 27.47 ± 4.06** 85.27 ± 4.89 39.27 ± 6.21**
* ImMDDC is immature MDDC. mMDDC is mature MDDC. Generation of each cell is described in the “Methods”.
**showed significant differences compare to non-treated (Tukey test, p < 0.05).
Setiyono et al. BMC Immunology 2011, 12:4
http://www.biomedcentral.com/1471-2172/12/4
Page 2 of 7CD83 was observed [from 80.97% to 27.17% in one experi-
ment and 75.6% to 23% in another (Table 1 and 2)].
The same effect was seen for CD80 (Table 2). The AFP
immunoregulatory activity is dose-dependent as less sup-
pression was seen at lower AFP concentrations (Table 2).
When individual AFP domain proteins were added at
0.091 μM, D1-AFP exhibited little suppressive effect on
CD83 (59.27 ± 8.90). In contrast, D2-AFP and D3-AFP
showed the same suppressive activities as the full-length
AFP protein (Table 1). We concluded that D2-AFP and
A
B 
C 
D
Figure 2 Effect of AFP domains on MDDC maturation and function in vitro. (A) CD14 expression pattern during DC maturation.
Examination of surface markers for (B) HLA-DR and CD11c, (C) CD40 and CD83, and (D) CD80 and CD86 to monitor MDDC function.
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of MDDC.
Impact of the domains on MDDC function in vitro
HLA-DR and CD11c were then used for further MDDC
characterization. In the presence of 0.091 μMD 2 - A F P
or D3-AFP, MDDC culture failed to up-regulate HLA-
DR. In contrast, 0.091 μM D1-AFP treated MDDC cul-
ture showed high level of HLA-DR expression. The
effect of D2-AFP and D3-AFP on the expression
of HLA-DR
high was similar to the FL-AFP molecules
(Figure 2B). Consistent with the HLA-DR results, expres-
sion of CD11c molecule was suppressed at day 8 by full-
length AFP (53.70 ± 3.94). The expression of HLA-
DR
high/CD11c
high was found to be repressed by D2-AFP
(41.57 ± 6.20) and D3-AFP (43.80 ± 6.91) at day 8 (Table
1). This indicated that both D2-AFP and D3-AFP showed
a similar suppressive effect to the expression of HLA-
DR
high/CD11c
high as the full-length AFP molecules.
In the absence of AFP or domains, CD40 was highly
expressed after LPS induction (day 8) as shown in Figure 2.
In contrast, addition of 0.091 μM AFP repressed the ability
of MDDC to express CD40 as shown in Table 1 (65.57 ±
0.30) at day 8 (bottom panel). In the presence of 0.091 μM
D2-AFP or D3-AFP, CD40 expression was altered when
compared to non-treated group. However, it was shown
that number of CD40
+/CD83
+ cells was reduced by
D 2 - A F Pa n dD 3 - A F Pb u tn o tD 1 - A F P( F i g u r e2 C ) .W e
concluded that the expression of CD40
+ and CD83
+ on
MDDC was suppressed when the D2-AFP or D3-AFP was
present.
As shown in Figure 2D, after LPS induction, expres-
sion of CD80
+/CD86
high was significantly inhibited by
0.091 μM D2-AFP (28.20 ± 4.59) or D3-AFP (27.47 ±
4.06) in a similar effect to the full-length AFP protein
(17.67 ± 2.35). In combination with HLA-DR
high expres-
sion, we concluded that the presence of D2-AFP or
D3-AFP is likely to block the ability of MDDC to pre-
sent antigens. We found that there was no significant
difference in the expression of CD80
+/CD86
high when
D1-AFP is present during MDDC maturation.
Effect of FL-AFP or D-AFP on IL-12 secretion
Level of cytokine IL-12 (p70) in supernatant of each
MDDC culture was measured using ELISA at day 6
(immature MDDC) and after 48 hrs stimulation with
LPS (mature MDDC). Before LPS stimulation, there was
very low IL-12 produced by both non-treated and trea-
ted group (Table 3). After 48 hrs of LPS stimulation, a
significant increase of IL-12 production was detected in
the non-treated group but not in the groups treated by
FL-AFP or any of the D-AFP samples. These results
suggested that both FL-AFP and D-AFP can impair the
ability of MDDC to produce IL-12 (p70).
Figure 3 FL-AFP reduced the viability of MDDC population at high concentrations. Addition of AFP 12.50 μg/ml or above resulted in a
significant cell death of MDDC population based on propidium iodide (PI) assay. PI staining was performed on MDDC culture at day 8, and
analyzed with flow cytometry. The viability of MDDC was determined as percentage of negative PI cells. The graphics shown are a representative
of three experiments with similar results.
Table 2 The viability of MDDC and expression of some surface markers on the mature MDDC treated with FL-AFP at
different concentration
Cell viability (%) Surface marker expression (%)
PI
+ PI- CD80
+ CD86
+ CD83
+
Non Treated 1.7 ± 1.0 98.3 ± 1.0 92.3 ± 5.8 99.4 ± 0.6 75.6 ± 24.1
FL-AFP 1.56 μg/ml 2.4 ± 1.7 97.6 ± 1.7 77.1 ± 20.1 98.8 ± 1.1 48.4 ± 21.7
FL-AFP 3.12 μg/ml 3.3 ± 2.2 96.7 ± 2.2 56.3 ± 27.5 99.1 ± 0.4 36.3 ± 21.8
FL-AFP 6.25 μg/ml 3.5 ± 1.1 96.5 ± 1.1 30.9 ± 28.7* 98.7 ± 0.8 23.0 ± 19.8*
FL-AFP 12.5 μg/ml 10.9 ± 5.8 89.1 ± 5.8 31.4 ± 12.6* 92.4 ± 10.2 38.1 ± 14.7
FL-AFP 25 μg/ml 28.2 ± 10.2* 71.8 ± 10.2* 30.0 ± 0.2* 89.7 ± 9.8 2.5 ± 1.6*
* showed significant differences compare to non treated (Tukey test, p < 0.05).
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We investigated the effects of AFP domains on MDDC
biology in vitro. The study was started by evaluating the
effects of AFP full length (FL-AFP) on the viability of
MDDC generated from healthy individuals. Using the
E. coli system and purification procedure as previously
reported [5], we could produce the domains of AFP in
E. coli. In this study, we have delineated the AFP
domains that execute the suppressive effect to MDDC
maturation. Furthermore, we were interested to see
whether after maturation, the MDDC can still function
in the presence of the AFP domains. For antigen presen-
tation, the engagement of the T-cell receptor by pep-
tide/MHC complexes (signal 1) is not sufficient to
trigger a T cell response, and that ligation of a co-
stimulatory receptor (signal 2) is required for T cell acti-
vation [6]. In addition, CD40 is also necessary for DC
activation [7-10]. Binding CD40 with CD40 ligand will
trigger downstream functions of DC such as cytokine
secretion. We divided the MDDC functions into the
ability to present the antigen and to secrete the cytokine
by monitoring the expression of CD14
+,C D 8 3
+,H L A -
DR
high/CD11c
high,C D 4 0
+/CD83
+,C D 8 0
+/CD86
high and
IL-12 as shown in Table 1 and 2.
Differentiation of monocytes into MDDC was moni-
tored by the expression of CD14 and CD83 molecule.
During MDDC maturation, CD14 decreases and conver-
sely, CD83 rapidly increases after addition of LPS. The
presence of AFP molecule at the concentration 6.25 μg/ml
(0.091 μM) resulted in reduction of CD83 expression. Our
results showed that the D2-AFP and D3-AFP retained the
suppression effect on CD83 appearance. The suppression
effect of D2-AFP and D3-AFP was found to be similar to
FL-AFP during the maturation process. As MDDC
maturation was repressed, we predict that the function of
MDDC would also be suppressed if we added the D2-AFP
and D3-AFP.
As shown in Table 1, cells that expressed HLA-
DR
high/CD11c
high,C D 4 0
+/CD83
+,a n dC D 8 0
+/CD86
high
were significantly lower in the presence of D2-AFP and
D3-AFP but comparable to the AFP molecules. This
finding suggests that these two domains contain the
suppression function to MDDC maturation and that
D2-AFP or D3-AFP potentially could be used for further
study to unravel the role of AFP in the immune system.
Secretion IL-12 in the form of the biologically active
p70 molecule could be considered to be one of the most
important functions of DCs. IL-12p70 produced by DCs
can polarize T cell responses towards CD4+ T helper 1
cells (Th1). Th1 cells can support development of CD8+
cytotoxic T lymphocytes and in turn, can foster an
appropriate adaptive immune response to eliminate
malignant cells [11]. It has been reported that LPS from
E. coli could induce MDDC to produce IL-12p70 [12].
However in the presence of the full-length AFP or AFP
domains, the production was blocked. These data sug-
gest a differential function of AFP domains in MDDC
maturation and cytokine secretion.
AFP is a glycoprotein protein. The recombinant AFP
fragments used in our study were expressed in E. coli,
which does not have a glycosylation system. It is inter-
esting to note that they were still functional in regulat-
ing MDDC function similarly to the full-length AFP
d e r i v e df r o mp u r i f i e dh u m a nc o r db l o o ds e r u m ,w h i c h
presumably are glycosylated. These results indicated that
glycosylation of AFP seems to be unnecessary in their
immunoregulatory function. Our result was also sup-
ported by a study on the effect of glycosylation on AFP
foldability and conformational structure performed by
others [13]. Using reversed-phase column HPLC to ana-
lyze two AFP variants: glycosylated cord blood-derived
AFP and non-glycosylated recombinant AFP purified
from transgenic goat milk, they showed that glycosyla-
tion is not required for proper protein folding of the
human AFP recombinant proteins. They presumed that
this is due to the presence of only one single glycosyla-
tion site in human AFP [2] and glycosylation does not
have a significant impact on the hydrophobicity or disul-
fide conformation of the molecule.
It has been reported that DC can be transfected or
pulsed with antigens to enhance cytotoxic lymphocyte
(CTL) responses [14]. In the context of DC-based
immunotherapy, AFP has been considered as a candi-
date antigen to elicit effective tumor rejection [15,16]
but its suppressive activities on DC function have pre-
cluded its implementation. Our results indicated that
individual AFP domains have differential effects on
MDDC maturation and function with D1-AFP having
the least suppressive activities. D1-AFP can thus
potentially be used as an antigen to pulse MDDC to
enhance CTL response against AFP. However, further
investigations in vitro and in vivo are still needed to
test this idea.
Conclusions
In conclusion, the AFP domains indeed have differential
immunoregulatory function. In the context of MDDC
Table 3 Production of IL 12 during MDDC maturation
process
Treatment IL12 (pg/ml)
imMDDC mMDDC
Non Treated 4.63 ± 2.68 148.13 ± 85.52
FL-AFP 1.60 ± 0.92 0.67 ± 0.38
D1-AFP 1.00 ± 0.58 3.63 ± 2.10
D2-AFP 1.80 ± 1.04 3.67 ± 2.12
D3-AFP 5.03 ± 2.91 1.37 ± 0.79
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suppressive function as the full-length AFP molecule. As
D1-AFP has no effect on DC function, it is a prime can-
didate for use in a DC-based immunotherapy.
Methods
Cloning and expression of the AFP domains
A complete AFP cDNA including its 5’-untranslated
region (5’-UTR) was synthesized by reverse-transcription
polymerase chain reaction (RT-PCR) from HepG2 total
RNA. RT-PCR was performed using Access Quick RT-
PCR System (Promega, Wisconsin, USA) with specific
AFP primers (forward primer F1: 5’-CTAAGGATC-
CATGAAGTGGGTGGAATC-3’ and reverse primer R3:
5’- GAGAATTCTTAAACTCCCAAAGCAGCACGAG-
3’). The resulting fragment was directly cloned into the
TOPO 2.1 vector (Invitrogen, CA, USA). The pET21b
clones containing D1 and D2 were verified by sequen-
cing. All the fusion proteins contain 14 amino acid (aa)
at their N-terminal ends (MASMTGGQQMGRDP) and
8 aa at their C-terminal ends (LEHHHHHH) derived
from pET21b vector. For D3 construct, pET21d was
used as a backbone (NcoI/XhoI). E. coli DH5a and BL21
(DE3) were utilized for maintenance and expression,
respectively. Expression of proteins was induced by Iso-
propyl b-D-1-thiogalactopyranoside (IPTG) and con-
firmed by ECL™ Western Blotting Detection Systems
(GE Healthcare, Uppsala, Sweden) using anti-His anti-
body according to manufacturer’s protocol.
Isolation, refolding, and purification
Recombinant D-AFPs were purified based on previous
report [5] with some modifications. Frozen cell pellet
from 200 ml culture was resuspended in 1 ml buffer B
(0.02 M Tris-Cl, 0.3 M NaCl, pH 8.0). The cell suspen-
sion was sonicated on an ultrasonic disintegrator high
intensity ultrasonic processor 750 W series (Sonics and
Materials, Danbury, USA) (12 × 5s, 4°C) and centrifuged
(12,000 g, 10 min, 4°C). The pellet was resuspended in
1.6 ml buffer B and centrifuged (12,000 g,1 0m i n ,4 ° C ) .
This procedure was repeated five times. 1.3 ml buffer A
(0.1 M Tris-Cl buffer, 6 M guanidine chlorides, pH 8.0)
was used to wash bacterial inclusion bodies continued
with sonication (12 × 5s, 4°C) and centrifuged (12,000 g,
30 min, 4°C). The supernatant was collected and filtered
with a Millex-HV PVDF 0.45 μm (Millipore, Massachu-
setts, USA) and applied onto 2 ml Ni-NTA superflow
column (Invitrogen, Carlsbad, USA). The sorbent was
washed consecutively with 3.3 ml buffer A and 3.3 ml
buffer C (0.05 M Tris-Cl, 6 M Urea, 0.4 M NaCl, and
0.02 M Imidazole, pH 8.0). The protein was eluted in
2 ml buffer D (0.05 M Tris-HCl, 6 M Urea, 0.4 M NaCl,
and 0.3 M Imidazole, pH 8.0). Each fraction from col-
umn was collected and analyzed by SDS-PAGE. The D
fraction was further concentrated on Amicon stirred cell
supplied with a PM-10 membrane (MW cutoff 10 kDa)
(Millipore, Massachusetts, USA), and clarified through a
Millex-HV PVDF 0.45 μm membrane filter.
Beta-mercaptoethanol was added at the final concen-
tration of 0.1 M and incubated for 1 h at room tempera-
ture with continuously stirring. The reduced protein was
mixed with 60 ml cold buffer E (0.1 M Tris-HCl, 0.5 M
NaCl, 2 mM EDTA, pH 8.0) for 48 h and dialyzed con-
secutively against buffer E (3L, 48h, 4°C) and buffer F
( 0 . 0 1MT r i s - H C l ,0 . 1 5MN a C l ,p H8 . 0 ;3 L ,2 4 h ,4 ° C ) .
The dialyzed protein was concentrated in an Amicon
stirred cell supplied with a PM-10 membrane (MW cut-
off 10 kDa) and passed through a Superdex™ 200 10/30
column (Amersham Pharmacia Biotech) with buffer F.
The purified protein was analyzed by SDS PAGE.
Isolation of peripheral blood mononuclear cell (PBMC)
from blood
The total of 198 ml blood used in this study was
obtained from 8 healthy volunteers with the age of 25 to
35 years old. Informed consent was obtained and the
ethical approval was granted from Committee on Health
Research Ethics of the Mochtar Riady Institute for
Nanotechnology. To obtain monocytes as progenitor
cell for generating MDDC, we used vacutainer
® with
heparin (BD vacutainer) during the phlebotomy proce-
dure. PBMC were then prepared using Ficoll-hypaque
(GE Health Care, UK) density gradient separation of
phlebotomy products.
Generation of monocyte-derived dendritic cell (MDDC)
MDDC were generated as described previously [17] with
some modifications. In brief, PBMC were adhered to 12
well culture plates with density 1 × 10
6 ml
-1 for 30 min
at 37°C with 5% CO2. The non adherent cells were
removed by gentle wash and the adherent cells were
then cultured in complete medium [RPMI 1640 (Sigma)
supplemented with 10% heat-inactivated fetal bovine
serum (Gibco), and contained rh-GM-CSF (800 U/ml,
BD Bioscience Pharmingen) and rh-IL-4 (1000 U/ml,
BD Bioscience Pharmingen]. Where indicated, purified
human cord blood AFP (FL-AFP, purity > 95%; Mono-
bind method; Lee Biosolutions, Inc) or each D-AFP was
added at day 0 for both immature and mature MDDC
stage. Culture was fed with complete medium on day 3
and day 5. The immature MDDC analysis was per-
formed at day 6 by collecting the non-adherent cell
from each group. Mature MDDC were obtained by
transferring the non-adherent cell to another fresh 12
well plates and LPS 500ng/ml (Sigma Aldrich) was then
added to induce MDDC maturation. Forty-eight hours
later, the non-adherent cell from each group were col-
lected and used for analysis. Each culture supernatant
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within 1 month later.
Analysis of MDDC surface markers and viability
Monocytes, immature and mature MDDC were stained
with CD14 PE (M5E2), HLA-DR FITC (G46-6), CD11c-
PE (B-ly6), CD86-PE (2331 FUN-1), CD80-FITC
(L307.4), CD40 FITC (5C3), CD83-PE (Hb15e) and rele-
vant isotype control (BD Bioscience Pharmingen), for 30
minutes at 4°C. The cells were then washed with PBS
containing 1% FBS. For cell viability determination, cells
were stained with Propidium Iodide (PI) at final concen-
tration 1 μg/ml. The cells were then analyzed within
24 hrs on FACS Epic Altra (Beckman Coulter) and
gated according to their size (forward light scatter) and
granularity (side light scatter).
Quantitative measurement of secreted IL-12 by enzyme-
linked immunosorbent assay (ELISA)
T oo b s e r v et h ea b i l i t yo fm a t u r eM D D Ct op r o d u c e
IL-12, stored supernatants from whether immature or
mature MDDC cultures were thawed and analyzed with
the Human IL-12(p70) ELISA Set (BD Bioscience)
according to the manufacturer’s instruction with detec-
tion range between 7.8-500 pg/ml.
Statistical analysis
The DC surface marker expression was analyzed using
EXPO32 ADC Analysis Software (Beckman Coulter).
One way ANOVA (Tukey test) was used to compare
more than two independent groups.
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